PFIZER INC

PFESEC EDGAR

Pharmaceutical Preparations(DE)CIK: 78003

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	$73.6B	—	$40.9B
Cost of Goods and Services Sold	$25.0B	$34.3B	$30.8B	$8.5B	$8.1B
Selling, General and Administrative Expense	$14.8B	$13.7B	$12.7B	$11.6B	$12.7B
Interest Expense	$2.2B	$1.2B	$1.3B	$1.4B	$1.6B
Other Nonoperating Income (Expense)	-$222.0M	-$1.1B	$4.9B	-$1.2B	-$3.5B
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$1.1B	$34.7B	$24.3B	$7.0B	$11.3B
Income Tax Expense (Benefit)	-$1.1B	$3.3B	$1.9B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$213.4B	$226.5B	$197.2B	$181.5B	$154.2B
Assets, Current	$50.4B	$43.3B	$51.3B	$59.7B	$35.1B
Cash and Cash Equivalents, at Carrying Value	$1.0B	$2.9B	$416.0M	$1.9B	$1.8B
Accounts Receivable, after Allowance for Credit Loss, Current	$11.5B	$11.6B	$11.0B	$11.5B	$7.9B
Inventory, Net	$10.9B	$10.2B	$9.0B	$9.1B	$8.0B
Liabilities	$124.9B	$137.2B	$101.3B	$104.0B	$90.8B
Liabilities, Current	$43.0B	$47.8B	$42.1B	$42.7B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$8.7B	$29.3B	$32.6B	$14.4B	$12.6B
Net Cash Provided by (Used in) Investing Activities	-$32.3B	-$15.8B	-$22.5B	-$4.3B	-$3.9B
Net Cash Provided by (Used in) Financing Activities	$26.1B	-$14.8B	-$9.8B	-$9.6B	-$8.5B
Payments to Acquire Property, Plant, and Equipment	$3.9B	$3.2B	$2.7B	$2.2B	$2.0B
Payments for Repurchase of Common Stock	—	$2.0B	$0.00	$0.00	$8.9B

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)